Dividend
-
-
-
-
-
-
-
BioVie Inc. Announces Proposed Public Offering of Common Stoc
-
-
-
-
-
-
-
BioVie to Present Blinded Data on NE3107 in the Treatment of Mild to Moderate Alzheimer’s Disease at CTAD
-
-
-
-
-
-
-
BioVie Announces Additional Findings from Phase 2 Alzheimer’s Disease Trial: NE3107 Appears to Impact Biomarkers of Aging-Related Disease States in Addition to Observed Reversal of Cognitive Decline
-
-
-
-
-
-
-
BioVie’s Phase 2 Trial Assessing NE3107's Pro-motoric Activity in Parkinson's Disease is Fully Enrolled
-
-
-
-
-
-
-
BioVie to Participate at the Oppenheimer Virtual Annual Healthcare Conference
-
-
-
-
-
-
-
BioVie Inc. (BIVI) Receives FDA Clearance to Commence Phase 2 Trials Assessing NE3107’s Pro-motoric Activity in Parkinson’s Disease
-
-
-
-
-
-
-
BioVie Inc. Announces Pricing of Public Offering of Common Stock
-
377,482 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All